Photobiomodulation therapy in neurodegenerative diseases: mechanisms, clinical applications, and future directions
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Photobiomodulation (PBM) therapy, using red to near-infrared light (600-1,000 nm), is becoming a promising non-invasive treatment for neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. This review examines the mechanistic insights and the preclinical and clinical evidence supporting the efficacy of PBM in enhancing mitochondrial function, reducing oxidative stress, and modulating neuroinflammation. The impact of PBM therapy on cellular energy production, gene expression, and inflammatory responses provides a comprehensive therapeutic approach targeting multiple pathological pathways in neurodegenerative conditions. Preclinical studies demonstrated the potential of PBM therapy in improving neuronal health and cognitive function, while early clinical trials revealed significant benefits in motor performance and cognitive outcomes with minimal adverse effects. By highlighting the necessity for personalized PBM therapy and its integration with other therapeutic modalities, the literature aims to optimize the treatment efficacy and expand the clinical applications of PBM technology. Further large-scale randomized controlled trials are essential to validate these findings and establish standardized treatment protocols, as current promising results position PBM as a viable and innovative therapeutic option for managing and potentially altering the course of neurodegenerative diseases.
Abstract
Photobiomodulation (PBM) therapy, using red to near-infrared light (600-1,000 nm), is becoming a promising non-invasive treatment for neurodegenerative diseases, such as Alzheimer’s disease, Parkinson’s disease, and amyotrophic lateral sclerosis. This review examines the mechanistic insights and the preclinical and clinical evidence supporting the efficacy of PBM in enhancing mitochondrial function, reducing oxidative stress, and modulating neuroinflammation. The impact of PBM therapy on cellular energy production, gene expression, and inflammatory responses provides a comprehensive therapeutic approach targeting multiple pathological pathways in neurodegenerative conditions. Preclinical studies demonstrated the potential of PBM therapy in improving neuronal health and cognitive function, while early clinical trials revealed significant benefits in motor performance and cognitive outcomes with minimal adverse effects. By highlighting the necessity for personalized PBM therapy and its integration with other therapeutic modalities, the literature aims to optimize the treatment efficacy and expand the clinical applications of PBM technology. Further large-scale randomized controlled trials are essential to validate these findings and establish standardized treatment protocols, as current promising results position PBM as a viable and innovative therapeutic option for managing and potentially altering the course of neurodegenerative diseases.
참고문헌 (56)
- Woo K, "Photobiomodulation improves the therapeutic efficacy of mesenchymal stem cells in regenerative medicine", Med Lasers, 11, pp.134~142 (2022)
- Dompe C, "Photobiomodulation-underlying mechanism and clinical applications", J Clin Med, 9, pp.1724~ (2020)
- Ebrahimpour-Malekshah R, "Combined therapy of photobiomodulation and adipose-derived stem cells synergistically improve healing in an ischemic, infected and delayed healing wound model in rats with type 1 diabetes mellitus", BMJ Open Diabetes Res Care, 8, pp.e001033~ (2020)
- Kim HB, "Pulse frequency dependency of photobiomodulation on the bioenergetic functions of human dental pulp stem cells", Sci Rep, 7, pp.15927~ (2017)
- Szymczyszyn A, "Effect of the transdermal lowlevel laser therapy on endothelial function", Lasers Med Sci, 31, pp.1301~1307 (2016)
- Shen Q, "Photobiomodulation for neurodegenerative diseases : a scoping review", Int J Mol Sci, 25, pp.1625~ (2024)
- Harding BN, "Spectrum of neuropathophysiology in spinal muscular atrophy type I", J Neuropathol Exp Neurol, 74, pp.15~24 (2015)
- Hague SM, "Neurodegenerative disorders : Parkinson’s disease and Huntington’s disease", J Neurol Neurosurg Psychiatry, 76, pp.1058~1063 (2005)
- Martin JB, "Molecular basis of the neurodegenerative disorders", N Engl J Med, 340, pp.1970~1980 (1999)
- Przedborski S, "Neurodegeneration : what is it and where are we?", J Clin Invest, 111, pp.3~10 (2003)
- Lamptey RNL, "A review of the common neurodegenerative disorders : current therapeutic approaches and the potential role of nanotherapeutics", Int J Mol Sci, 23, pp.1851~ (2022)
- Bhatt R, "Development, characterization and nasal delivery of rosmarinic acid-loaded solid lipid nanoparticles for the effective management of Huntington’s disease", Drug Deliv, 22, pp.931~939 (2015)
- Schulz-Schaeffer WJ, "The synaptic pathology of alpha-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia", Acta Neuropathol, 120, pp.131~143 (2010)
- Moore DJ, "Molecular pathophysiology of Parkinson’s disease", Annu Rev Neurosci, 28, pp.57~87 (2005)
- Bartels AL, "Parkinson’s disease : the syndrome, the pathogenesis and pathophysiology", Cortex, 45, pp.915~921 (2009)
- Spires-Jones TL, "Interactions of pathological proteins in neurodegenerative diseases", Acta Neuropathol, 134, pp.187~205 (2017)
- Poyton RO, "Therapeutic photobiomodulation : nitric oxide and a novel function of mitochondrial cytochrome c oxidase", Discov Med, 11, pp.154~159 (2011)
- de Freitas LF, "Proposed mechanisms of photobiomodulation or low-level light therapy", IEEE J Sel Top Quantum Electron, 22, pp.7000417~ (2016)
- Watson SA, "Functions of cytochrome c oxidase assembly factors", Int J Mol Sci, 21, pp.7254~ (2020)
- Hamblin MR, "Photobiomodulation or low-level laser therapy", J Biophotonics, 9, pp.1122~1124 (2016)
- Rangaraju V, "Pleiotropic mitochondria : the influence of mitochondria on neuronal development and disease", J Neurosci, 39, pp.8200~8208 (2019)
- Kowalczyk P, "Mitochondrial oxidative stress-a causative factor and therapeutic target in many diseases", Int J Mol Sci, 22, pp.13384~ (2021)
- Oladele JO, "Reactive oxygen species" (2021), IntechOpen
- Rupel K, "Photobiomodulation at multiple wavelengths differentially modulates oxidative stress in vitro and in vivo", Oxid Med Cell Longev, 2018, pp.6510159~ (2018)
- Shields HJ, "Beneficial and detrimental effects of reactive oxygen species on lifespan : a comprehensive review of comparative and experimental studies", Front Cell Dev Biol, 9, pp.628157~ (2021)
- Huang YY, "Biphasic dose response in low level light therapy-an update", Dose Response, 9, pp.602~618 (2011)
- Oyebode OA, "Photobiomodulation at 830 nm stimulates migration, survival and proliferation of fibroblast cells", Diabetes Metab Syndr Obes, 15, pp.2885~2900 (2022)
- Jere SW, "Photobiomodulation and the expression of genes related to the JAK", STAT signalling pathway in wounded and diabetic wounded cells, 2020, pp.204, 111791~
- Evangelista AN, "Photobiomodulation therapy on expression of HSP70 protein and tissue repair in experimental acute Achilles tendinitis", Lasers Med Sci, 36, pp.1201~1208 (2021)
- DiSabato DJ, "Neuroinflammation : the devil is in the details", J Neurochem, 139(Suppl 2), pp.136~153 (2016)
- Abijo A, "The beneficial role of photobiomodulation in neurodegenerative diseases", Biomedicines, 11, pp.1828~ (2023)
- Song S, "Low-level laser therapy regulates microglial function through Src-mediated signaling pathways : implications for neurodegenerative diseases", J Neuroinflammation, 9, pp.219~ (2012)
- Salehpour F, "Brain photobiomodulation therapy : a narrative review", Mol Neurobiol, 55, pp.6601~6636 (2018)
- Chitnis T, "CNS inflammation and neurodegeneration", J Clin Invest, 127, pp.3577~3587 (2017)
- Zhou T, "Effect of NIR light on the permeability of the blood-brain barriers in in vitro models", Biomed Opt Express, 12, pp.7544~7555 (2021)
- Daneman R, "The blood-brain barrier", Cold Spring Harb Perspect Biol, 7, pp.a020412~ (2015)
- Abbott NJ, "Structure and function of the blood-brain barrier", Neurobiol Dis, 37, pp.13~25 (2010)
- Lu Y, "Low-level laser therapy for beta amyloid toxicity in rat hippocampus", Neurobiol Aging, 49, pp.165~182 (2017)
- Johnstone DM, "Turning on lights to stop neurodegeneration : the potential of near infrared light therapy in Alzheimer’s and Parkinson’s disease", Front Neurosci, 9, pp.500~ (2016)
- Bathina S, "Brain-derived neurotrophic factor and its clinical implications", Arch Med Sci, 11, pp.1164~1178 (2015)
- Wang S, "p75(NTR)mediates neurotrophin-induced apoptosis of vascular smooth muscle cells", Am J Pathol, 157, pp.1247~1258 (2000)
- Huang Z, "Photobiomodulation in experimental models of Alzheimer’s disease : state-of-the-art and translational perspectives", Alzheimers Res Ther, 16, pp.114~ (2024)
- Berman MH, "Photobiomodulation with near infrared light helmet in a pilot, placebo controlled clinical trial in dementia patients testing memory and cognition", J Neurol Neurosci, 8, pp.176~ (2017)
- Zein R, "Review of light parameters and photobiomodulation efficacy : dive into complexity", J Biomed Opt, 23, pp.1~17 (2018)
- Bicknell B, "Parkinson’s disease and photobiomodulation : potential for treatment", J Pers Med, 14, pp.112~ (2024)
- Alrouji M, "A story of the potential effect of non-steroidal anti-inflammatory drugs(NSAIDs)in Parkinson’s disease : beneficial or detrimental effects", Inflammopharmacology, 31, pp.673~688 (2023)
- Peoples C, "Photobiomodulation enhances Nigral dopaminergic cell survival in a chronic MPTP mouse model of Parkinson’s disease", Parkinsonism Relat Disord, 18, pp.469~476 (2012)
- Cheng XT, "Programming axonal mitochondrial maintenance and bioenergetics in neurodegeneration and regeneration", Neuron, 110, pp.1899~1923 (2022)
- Liebert A, "Remote photobiomodulation treatment for the clinical signs of Parkinson’s disease : a case series conducted during COVID-19", Photobiomodul Photomed Laser Surg, 40, pp.112~122 (2022)
- Herkes G, "A novel transcranial photobiomodulation device to address motor signs of Parkinson’s disease : a parallel randomised feasibility study", EClinicalMedicine, 66, pp.102338~ (2023)
- Ahrabi B, "Photobiomodulation therapy and cell therapy improved Parkinson’s diseases by neuro-regeneration and tremor inhibition", J Lasers Med Sci, 13, pp.e28~ (2022)
- Bonafede R, "ALS pathogenesis and therapeutic approaches : the role of mesenchymal stem cells and extracellular vesicles", Front Cell Neurosci, 11, pp.80~ (2017)
- Longo L, "Amyotrophic Lateral Sclerosis(ALS)treated with Low Level LASER Therapy(LLLT) : a case report", AIP Conf Proc, 1142, pp.72~74 (2009)
- Dubbioso R, "Autonomic dysfunction is associated with disease progression and survival in amyotrophic lateral sclerosis : a prospective longitudinal cohort study", J Neurol, 270, pp.4968~4977 (2023)
- Bathini M, "The molecular mechanisms of action of photobiomodulation against neurodegenerative diseases : a systematic review", Cell Mol Neurobiol, 42, pp.955~971 (2022)
- Salehpour F, "Penetration profiles of visible and nearinfrared lasers and light-emitting diode light through the head tissues in animal and human species : a review of literature", Photobiomodul Photomed Laser Surg, 37, pp.581~595 (2019)